NCT03540043

Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of PUR 0110 (Thykamine™) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 162 (actual)
• Sponsor: PurGenesis Technologies Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2, multicenter, double-blind, placebo control study evaluating the safety and efficacy of Thykamine in adult patient suffering of mild-to-moderate Atopic Dermatitis

Detailed description

4-week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of Three Concentrations (0.05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis.

Conditions

• Atopic Dermatitis Eczema

Interventions

Type	Name	Description
DRUG	Administration of Placebo	Botanical Drug Phase 2 clinical study
DRUG	Administration of PUR0110 (Thykamine) 0.05%	Botanical Drug Phase 2 clinical study
DRUG	Administration of PUR0110 (Thykamine) 0.1%	Botanical Drug Phase 2 clinical study
DRUG	Administration of PUR0110 (Thykamine) 0.25%	Botanical Drug Phase 2 clinical study

Timeline

• Start date: 2017-10-23
• Primary completion: 2019-12-31
• Completion: 2020-06-03
• First posted: 2018-05-30
• Last updated: 2021-09-16

Locations

12 sites across 1 country: Canada